a group of seasoned biopharma entrepreneurs, executives, and scientists
with proven track records of success on a global scale
Dr. Al Lin is an executive, scientist, physician, and investor. Dr. Lin has over 30 years of experience in novel drug discovery research, development, global regulatory approval, and medical practice. Prior to Innoland, he was Senior Vice President at FibroGen (USA) where he led global drug discovery and development functions, including drug discovery, preclinical research and development, Chemistry, Manufacturing, and Controls (CMC), Quality Management (QA, QC, CQA) and Supply Chain Management. Dr. Lin co-invented a number of new platform technologies and first-in-class medicines, most notably, the pioneering HIF-PH inhibition (2019 Nobel Prize science) platform and Roxadustat, a global first-in-class medicine that is marketed around the world. Prior to FibroGen, he held various R&D management positions at Bayer and Xoma with increasing responsibilities. Dr. Lin also has extensive experiences in angel investing, venture capital, private equity, M&A, and post-investment/post-M&A management. Dr. Lin received his Ph.D. from St. Louis University and completed post-doctoral training at University of Virginia. Prior to moving to the states, Dr. Lin practiced cardiology at Jiangsu Provincial People's Hospital after graduating from Nanjing Medical University.